ValitaCell

ValitaCell is a biotechnology startup with a vision to revolutionize the biopharmaceutical industry through pioneering analytical technologies. Since its establishment in 2014, the company has been dedicated to creating and commercializing innovative products to enhance quality control and performance in the biopharmaceutical sector. Through its cutting-edge products, ValitaCell aims to expedite the introduction of novel medicines to the market, offering a more cost-effective and expedited process while ensuring regulatory adherence. The company's commitment to leveraging artificial intelligence further underscores its ambition to be at the forefront of biological science and cell therapy. The recent €2.03M grant investment secured by ValitaCell on 01 October 2017 from EASME - EU Executive Agency for SMEs attests to the promising prospects of the company and the confidence it has garnered from esteemed investors. As of now, ValitaCell has become a part of the Beckman Coulter Life Sciences company, further solidifying its position in the industry. Based in Ireland, ValitaCell operates at the intersection of biotechnology, health care, and medical devices, positioning itself as a key player in driving advancements within these domains. With its innovative approach and strategic partnerships, ValitaCell is poised to continue making significant contributions to the biopharmaceutical landscape.